High-Risk Metachronous Oligometastatic Prostate Cancer Trial

NCT06212583 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Oligometastatic Disease

Interventions

DRUG: niraparib/abiraterone acetate
RADIATION: Stereotactic ablative radiation therapy (SABR)
DRUG: Androgen deprivation therapy (ADT)

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]